中国药物警戒 ›› 2012, Vol. 9 ›› Issue (4): 247-248.

• 个案分析 • 上一篇    下一篇

非霍奇金淋巴瘤患者化疗风险的评估及药学监护体会

文娱1，解方为2，欧阳学农2   

  1. 1 厦门市中医院药剂科，福建 厦门 361001；
    2 南京军区福州总医院肿瘤科，福建 福州350025
  • 收稿日期:2011-09-07 出版日期:2012-04-10 发布日期:2015-08-10

Risk Assessment and Pharmaceutical Care on a Patient with Non-Hodgkin Lymphoma Chemotherapy

WEN Yu1, XIE Fang-wei2, OUYANG Xue-nong2   

  1. 1 Pharmacy Department, Xiamen Hospita of Traditional Chinese Medicine, Fujian Xiamen 361001, China;
    2 Oncology department, Fuzhou General Hospital of Chinese PLA Nan-jing Military Command, Fujian Fuzhou 350025, China
  • Received:2011-09-07 Online:2012-04-10 Published:2015-08-10

PDF (PC)

231

摘要： 目的提示临床高度关注非霍奇金淋巴瘤患者化疗的风险。方法临床药师对1例复发、难治的非霍奇金淋巴瘤患者化疗过程中可能出现的肿瘤溶解综合征、乙肝病毒激活情况、骨髓抑制、血栓形成风险、迟发性腹泻、急性及迟发性呕吐进行评估，并实施药学监护。结果患者化疗过程中未出现严重不良反应，顺利完成本周期治疗。结论临床应具有非霍奇金淋巴瘤患者化疗的风险意识，提高用药安全性。

关键词: 临床药师, 非霍奇金淋巴瘤, 评估, 药学监护

Abstract: Objective To prompt the clinical to pay high attention to chemotherapy in patients with non-Hodgkin's lymphoma risk. MethodsThe clinical pharmacists assessed a recurrence and refractory non-Hodgkin's lymphoma patient during chemotherapy, with the potential risks of tumor dissolve syndrome,activation of hepatitis B virus, bone marrow inhibition, thrombosis, delayed diarrhea, acute and late-occurred vomiting evaluation,and implementation of pharmaceutical care. ResultsThe patient finished this cycle treatment with no serious adverse reactions during chemotherapy. ConclusionThe clinical professionals should be aware of the risks in the process of chemotherapy for non-Hodgkin lymphoma patients and improve the chemotherapy drug safety.

Key words: clinical pharmacist, non-Hodgkin lymphoma, assess, pharmaceutical care